

## Policies Repository



**Policy Title** Fesoterodine fumarate extended-release (Toviaz™)

**Policy Number** FS.CLIN.30

*Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.*

*This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.*

*Members are advised to use participating pharmacies in order to receive the highest level of benefits.*

**Policy** Fesoterodine fumarate extended-release (Toviaz™) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

The use of Fesoterodine fumarate extended-release (Toviaz™) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

**Policy Description** Fesoterodine fumarate extended-release (Toviaz™) is an antispasmodic agent. Active metabolite of fesoterodine is responsible for the antimuscarinic activity which prevents contractions of smooth muscle within the urinary bladder. There have been no clinical studies to demonstrate that this new therapy is more effective than

existing therapies.

## Policy Guideline Inclusion

**Fesoterodine fumarate extended-release tablets (Toviaz™)** is approved when **all** of the following inclusion criteria are met:

- Documentation of a diagnosis of overactive bladder
- Documentation of trial, failure or contraindication with **all** of the following:
  - Oxybutynin containing product
  - Enablex

## Policy Guideline Exclusion

**Fesoterodine fumarate extended-release tablets (Toviaz™)** is denied when **any** of the following exclusion criteria are found:

- No documentation of a diagnosis of overactive bladder
- No documentation of trial, failure or contraindication with **all** of the following:
  - Oxybutynin containing product
  - Enablex

## Policy List of Applicable Drugs

Brand Name	Generic Name
Toviaz	Fesoterodine fumarate extended-release

## Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

## Policy References

Toviaz™ (Fesoterodine fumarate extended-release tablets) [package insert]. New York, NY: Pfizer Labs; September 2010.

Toviaz™ (Fesoterodine fumarate extended-release tablets). In: Facts and Comparisons [online through Facts and Comparisons Online]. Indy, IN: Walter Kluwer Health Inc. Accessed August 11, 2010.

Toviaz™ (Fesoterodine fumarate extended-release tablets). In: Drugdex [online through Micromedex Healthcare Series]. Greenwood Village, CO: Thomson Micromedex. Accessed August 11, 2010.

## Policy Link to Related Policies

---

Printed

11/15/2010 09:14:51

---

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.

|